Pacific Therapeutics Ltd.

Presenter: Doug Unwin, President & CEO

Company Information

Company Type: Therapeutics

Development Stage: Private

Company Profile

Pacific Therapeutics is a development stage Specialty Pharmaceutical Company focused on the identification and development of drug candidates to treat diseases of excessive scarring (fibrosis). Its strategy includes reformulating approved drugs to increase efficacy and patient compliance, completing the further clinical testing, manufacturing and other regulatory requirements sufficient to seek marketing authorizations in the US, Europe and other countries. This strategy reduces the risk, time and cost of developing therapies for fibrosis by avoiding the risks associated with basic research and using compounds with unknown safety and toxicity profiles. Pacific leverages its expertise to manage and perform critical steps in drug development including the design and conduct of clinical trials, the development and execution of intellectual property strategies and the interaction with drug regulatory authorities.

The lead product candidate PTL-202 is a combination of drugs that have been approved by the FDA. In animal trials the combination was more effective than either of its components at reducing indicators of fibrosis. Pacific is planning to initiate a Phase I drug/drug interaction and colonic absorption study in H1 of 2010. Idiopathic pulmonary fibrosis is a $2 billion market opportunity.

Presenter Bio

Douglas H. Unwin, B.Sc., MBA

President and Chief Executive Officer & Director - Mr. Unwin, Pacific's founder and has served as President and Chief Executive Officer since the Company's inception in September 2005. Mr. Unwin is an experienced executive with 25 years of diverse experience including 23 years as an entrepreneur in Life Sciences, Aquaculture and Telecommunications. He has spent his last 9 years focused on Life Science start-ups, technology commercialization and venture capital financing. Mr. Unwin was an Associate with Neuro Discovery Inc. a venture capital company focused on investing in therapies for neurological disorders. Mr. Unwin developed the original business models that evolved into a successful specialty pharma. Prior to founding the Issuer, Mr. Unwin was the CEO of Med BioGene Inc. (MBI.TSX Venture) a start-up medical device company.

Contact

Pacific Therapeutics Ltd.
1023 - 409 Granville St.
Vancouver
BC, Canada
V6C 1T2

ph: (604) 738-1049
fx: (604) 738-1094

www.pacifictherapeutics.com
unwin@pacifictherapeutics.com